Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429403 · ClinicalTrials.gov registry record · Phase 3
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT00429403: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00429403 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429403, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing neoadjuvant and/or adjuvant chemotherapy for primary invasive breast cancer by documenting persistence or resumption of regular menses. Secondary Objectives: * To determine the incidence of pregnancy and the effect for participants' quality of life (QOL) after chemotherapy. * To determine the overall survival and disease-free survival times of study participants.
Interventions
- DRUG Goserelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429403
The ClinicalTrials.gov registry entry for NCT00429403 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Goserelin is the first listed.
NCT00429403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429403 about?
NCT00429403 is a clinical study titled "Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer". Primary Objective: * To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing neoadjuvant and/or adjuvant chemotherapy for primary invasive breast cancer by documenting persistence or resumption of regular menses. Secondary Obje...
What is the current status of trial NCT00429403?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2006-08. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00429403?
The interventions under investigation include: Goserelin (DRUG).
Who is sponsoring clinical trial NCT00429403?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.